Dose Escalation Reverses Antibody Formation and Loss of Response in Children with Inflammatory Bowel Disease Treated with Adalimumab
Year: 2025
Type: article
Abstract: In this study, we describe 4 children with inflammatory bowel disease (IBD) who had a reversal of adalimumab antibodies (AA) and regained clinical response following dose escalation of adalimumab. We observed in our cases that all of them benefitted from adalimumab dose escalation in terms of achieving clinical and laboratory remission as well as achieving desirable adalimumab trough level and reversal of adalimumab antibodies. Keywords: Inflammatory bowel disease, adalimumab antibodies, dose escalation.
Author: Dr. Elmunzir Ali
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Genetics
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7090344292
FWCI:
Cites:
Cited by:
Related to: